Aslan Pharmaceuticals Valuation
| ASLNDelisted Stock | USD 0.60 0.03 4.76% |
Aslan Pharmaceuticals is overvalued. Aslan Pharmaceuticals shows a prevailing Real Value of $0.57 per share. The current price of the firm is $0.6. Our model approximates the value of Aslan Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -4.27, profit margin of (2.92) %, and Current Valuation of 288.33 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Aslan Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Aslan Pharmaceuticals is based on 3 months time horizon. Increasing Aslan Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Aslan Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aslan Stock. However, Aslan Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.6 | Real 0.57 | Hype 0.6 | Naive 0.16 |
The intrinsic value of Aslan Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aslan Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aslan Pharmaceuticals helps investors to forecast how Aslan stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aslan Pharmaceuticals more accurately as focusing exclusively on Aslan Pharmaceuticals' fundamentals will not take into account other important factors: Aslan Pharmaceuticals Total Value Analysis
Aslan Pharmaceuticals is presently expected to have valuation of 288.33 M with market capitalization of 1.7 M, debt of 26.83 M, and cash on hands of 78.12 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aslan Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
288.33 M | 1.7 M | 26.83 M | 78.12 M |
Aslan Pharmaceuticals Investor Information
About 13.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 16.0. Aslan Pharmaceuticals had not issued any dividends in recent years. The entity had 1:8 split on the 3rd of July 2024. Based on the key indicators related to Aslan Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Aslan Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Aslan Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aslan Pharmaceuticals has an asset utilization ratio of 48.73 percent. This suggests that the Company is making $0.49 for each dollar of assets. An increasing asset utilization means that Aslan Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Aslan Pharmaceuticals Ownership Allocation
Almost 86.66 percent of Aslan Pharmaceuticals outstanding shares are held by general public with 0.14 (percent) owned by insiders and only 13.21 % by other corporate entities.Aslan Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 12 M. Net Loss for the year was (44.22 M) with profit before overhead, payroll, taxes, and interest of 79.82 M.About Aslan Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Aslan Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Aslan Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Aslan Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Aslan Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aslan Pharmaceuticals. We calculate exposure to Aslan Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aslan Pharmaceuticals's related companies.ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company was founded in 2010 and is headquartered in Singapore. Aslan Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 27 people.
Aslan Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16.4 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |